We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




PSA Can Help Identify Cancer Following Surgery for Benign Prostatic Hyperplasia

By HospiMedica International staff writers
Posted on 09 Jul 2009
Men undergoing surgical interventions for benign prostatic hyperplasia (BPH) are still at risk for subsequent development of prostate cancer due to residual tissue, claims a new study. More...


Researchers at Northwestern University (Chicago, IL, USA) conducted a retrospective review of 525 patients who had undergone one of three procedures for BPH: transurethral resection of the prostate (TURP; 343 patients), holmium laser resection of the prostate (HoLRP; 54 patients), or open prostatectomy (OP; 68 patients), between 1992 and 2007. The prostate-specific antigen (PSA) and PSA velocity values were collected at regular intervals both pre- and postoperatively for all patients, since the researchers hypothesized that the PSA level might be influenced by the efficacies of different BPH procedures. Only patients with histologic BPH and those with incidental prostate cancer who underwent a watchful waiting strategy were included.

The researchers found that the average preoperative PSA values were significantly different between the TURP, HoLRP, and OP groups. Only one patient had incidental prostate cancer in the HoLRP group. No differences were present between the preoperative PSA values for patients with histologic BPH and those with incidental prostate cancer undergoing a watchful waiting strategy. However, the postoperative PSA values were increased in the patients with prostate cancer; similarly, patients with incidental prostate cancer had a significantly elevated postoperative mean PSA velocity compared with patients without prostate cancer. The researchers therefore concluded that postoperative PSA and PSA velocity measurements could be used to distinguish patients with prostate cancer from those with histologic BPH only. The study was published ahead of print on May 8, 2009, in the online edition of Urology.

Prostatic adenoma inevitably remains after BPH surgery, and studies have determined that the level of PSA decreases by approximately 0.1-0.3 ng/ml for every gram of prostate tissue removed. Therefore, PSA levels should indicate residual hyperplastic tissue, as well as resulting cancer risk.

Related Links:

Northwestern University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.